Literature DB >> 15121034

Primary prevention in rheumatology: the importance of hyperuricemia.

Janitzia Vázquez-Mellado1, Everardo Alvarez Hernández, Rubén Burgos-Vargas.   

Abstract

Hyperuricemia (HU) is present in 5-30% of the general population, although the prevalence is higher among some ethnic groups and seems to be increasing worldwide. Classically, chronic HU has been considered a risk factor for gout or lithiasis and is associated with alcoholism, obesity, hypertension, dyslipidemia, hyperglycemia/diabetes mellitus, renal failure and intake of certain drugs. HU is also associated with cardiovascular diseases such as hypertension, vascular disease, pre-eclampsia, pulmonary arterial hypertension, stroke, heart failure, ischemic heart disease and also metabolic syndrome, renal disease and increased mortality. It is uncertain if these associations are dependent or not, especially cardiovascular and renal diseases. Patients with chronic HU and also those with gout require both medical investigation for associated diseases or drugs as well as nutritional counseling and life-style changes. HU should alert physicians to possible complications.

Entities:  

Mesh:

Year:  2004        PMID: 15121034     DOI: 10.1016/j.berh.2004.01.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  8 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

3.  Hyperuricemia and its related factors in an urban population, Izmir, Turkey.

Authors:  Ismail Sari; Servet Akar; Betul Pakoz; Ali Riza Sisman; Oguz Gurler; Merih Birlik; Fatos Onen; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2008-12-02       Impact factor: 2.631

4.  The association between hyperuricemia and the Trp64Arg polymorphism of the beta-3 adrenergic receptor.

Authors:  Young Hee Rho; Seong Jae Choi; Young Ho Lee; Jong Dae Ji; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2007-01-16       Impact factor: 3.580

5.  The prevalence of hyperuricemia in China: a meta-analysis.

Authors:  Liu B; Wang T; Zhao Hn; Yue Ww; Yu Hp; Liu Cx; Yin J; Jia Ry; Nie Hw
Journal:  BMC Public Health       Date:  2011-10-27       Impact factor: 3.295

6.  Xanthine oxidase inhibitory activity of the methanolic extracts of selected Jordanian medicinal plants.

Authors:  Mohammad M Hudaib; Khaled A Tawaha; Mohammad K Mohammad; Areej M Assaf; Ala Y Issa; Feras Q Alali; Talal A Aburjai; Yasser K Bustanji
Journal:  Pharmacogn Mag       Date:  2011-10       Impact factor: 1.085

7.  Hyperuricemia and Its Associated Factors Among Adult Staff Members of the Ethiopian Public Health Institute, Ethiopia.

Authors:  Meseret Derbew Molla; Abebe Bekele; Daniel Seifu Melka; Maria Degef Teklemariam; Feyissa Challa; Birhanu Ayelign; Tewodros Shibabaw; Yonas Akalu; Zeleke Geto
Journal:  Int J Gen Med       Date:  2021-04-20

8.  Risk factors analysis for hyperuricemic nephropathy among CKD stages 3-4 patients: an epidemiological study of hyperuricemia in CKD stages 3-4 patients in Ningbo, China.

Authors:  Yong-Yao Wu; Xiao-Hui Qiu; Yun Ye; Chao Gao; Fuquan Wu; Guihua Xia
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.